Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Salvatore Maria Corsello; Roberto Salvatori; Agnese Barnabei; Liana De Vecchis; Paolo Marchetti; Francesco Torino

doi:10.1007/s00280-013-2213-y

Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Salvatore Maria Corsello
, Roberto Salvatori
, Agnese Barnabei
, Liana De Vecchis
, Paolo Marchetti
, Francesco Torino

Università Cattolica del Sacro Cuore

Johns Hopkins University
IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
University of Rome Tor Vergata
Sant'Andrea Hospital

Research output: Contribution to journal › Article

11 Citations (Scopus)

Abstract

With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufﬁciency

Original language	English
Pages (from-to)	489-490
Number of pages	2
Journal	Cancer Chemotherapy and Pharmacology
Volume	72
DOIs	https://doi.org/10.1007/s00280-013-2213-y
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adrenal Cortex Hormones
Anti-Inflammatory Agents
Antibodies, Monoclonal
Endocrine System Diseases
Humans
Hypopituitarism
Methylprednisolone
Neoplasms
Prednisone
Thyroid Diseases

Access to Document

10.1007/s00280-013-2213-y

Cite this

@article{d02e92498c9b4c728ddb7dd9a69eb620,

title = "Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)",

abstract = "With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0{\textendash}17 \%), thyroid disease or abnormalities in thyroid function tests (0{\textendash}2 \%), and occasionally primary adrenal insufﬁciency",

keywords = "Adrenal Cortex Hormones, Anti-Inflammatory Agents, Antibodies, Monoclonal, Endocrine System Diseases, Humans, Hypopituitarism, Methylprednisolone, Neoplasms, Prednisone, Thyroid Diseases, Adrenal Cortex Hormones, Anti-Inflammatory Agents, Antibodies, Monoclonal, Endocrine System Diseases, Humans, Hypopituitarism, Methylprednisolone, Neoplasms, Prednisone, Thyroid Diseases",

author = "Corsello, \{Salvatore Maria\} and Roberto Salvatori and Agnese Barnabei and \{De Vecchis\}, Liana and Paolo Marchetti and Francesco Torino",

year = "2013",

doi = "10.1007/s00280-013-2213-y",

language = "English",

volume = "72",

pages = "489--490",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

AU - Corsello, Salvatore Maria

AU - Salvatori, Roberto

AU - Barnabei, Agnese

AU - De Vecchis, Liana

AU - Marchetti, Paolo

AU - Torino, Francesco

PY - 2013

Y1 - 2013

N2 - With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufﬁciency

AB - With the expanding use of ipilimumab, oncologists are not only faced with most common side effects, such as diarrhea and rush, but also with unusual adverse events, such as certain endocrinopathies. These include hypophysitis (0–17 %), thyroid disease or abnormalities in thyroid function tests (0–2 %), and occasionally primary adrenal insufﬁciency

KW - Adrenal Cortex Hormones

KW - Anti-Inflammatory Agents

KW - Antibodies, Monoclonal

KW - Endocrine System Diseases

KW - Humans

KW - Hypopituitarism

KW - Methylprednisolone

KW - Neoplasms

KW - Prednisone

KW - Thyroid Diseases

KW - Adrenal Cortex Hormones

KW - Anti-Inflammatory Agents

KW - Antibodies, Monoclonal

KW - Endocrine System Diseases

KW - Humans

KW - Hypopituitarism

KW - Methylprednisolone

KW - Neoplasms

KW - Prednisone

KW - Thyroid Diseases

UR - http://hdl.handle.net/10807/52890

U2 - 10.1007/s00280-013-2213-y

DO - 10.1007/s00280-013-2213-y

M3 - Article

SN - 0344-5704

VL - 72

SP - 489

EP - 490

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

ER -

Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this